الفهرس 
Non-Hodgkin’s LymphomaOnly 14 pages are availabe for public view
 |  | from | 309 |  |  |
| | | from | 309 | | |
Abstract
Introduction: Lymphatic cancers are classified by the type of immune cells affected. There are two main types of lymphomas including Hodgkin lymphoma, an uncommon form of lymphoma that involves an abnormal type of B lymphocyte, named Reed-Sternberg cells. Aim of the work: The aim of retrospective study is to evaluate the outcome of cyclophosamide, melphalan and etoposide as a conditioning regimen in autologous bone marrow transplantation for relapsed lymphomas regarding: Disease free survival (DFS), overall survival (OS) and transplantation related toxicity and mortality. Patients and Methods: Patients with relapsed or refractory lymphomas who underwent autologous bone marrow transplantation using cyclophosamide, melphalan and etoposide as conditioning regimen in Al Sheikh Zayed specialized Hospital. Patients files reviewed regarding: Demographic data: age, sex, initial diagnosis: (NHL, HL), stage of disease after diagnosis, pre- and post -transplant evaluation including: full clinical examination, laboratory assessment (hematological assessment, liver function tests, and kidney function tests), radiological assessment (CT neck, chest, abdomen and pelvis with contrast, PET CT). Results: The present study shows that Overall survival at 24 months is 77% and at 60 months is 64.5%. Conclusion: the current study showed that Overall survival at 24 months is 77% and at 60 months is 64.5%. Also, Disease free survival at 24 months is 73% and at 60 months is 63%. Recommendations: Further studies with more closed follow up for longer time are needed for relapsed and refractory lymphoma patients who under autologous bone marrow transplantation using CMV regimen in conditioning. Further studies on the outcome of CMV regimen in comparison with other conditioning regimens in autologous bone marrow transplantation. Further studies with larger sample size are needed to objectively charge our study.